Alliance for Vascular Access Teaching and Research Group

Alliance for Vascular Access Teaching And Research

Search
  • Home
  • About Us
    • About Us
    • Our Team
    • Our Sponsors
    • Our Partners
    • Consumer Engagement
    • Upcoming Events
    • Newsletters
    • Useful Links
    • Contact Us
  • Teaching
    • Clinical Practice Guidelines
    • Cochrane Reviews
    • CVAD Resources For Patients
    • Education and Evidence-Based Practice
    • Essentials of EBP
    • Multimedia Learning Resources
    • Vascular Access Device Types
    • Veins of the Chest and Neck
    • Ultrasound Workshop
  • Research
    • Acute and Critical Care
    • Current Research Projects
    • Experimental Laboratory Science (XLabS)
    • Health Services, Quality and Safety
    • Infection Prevention and Control
    • Paediatrics and Neonates
  • Publications
  • Innovations
    • Difficult IV Access Resources
    • I-DECIDED
    • IV Passport
    • miniMAGIC
  • Blog
  • FAQs
  • Support
    • Donate
    • Educational Support
  • facebook
  • youtube
  • linkedin

Intravascular device administration sets: Replacement after Standard Versus Prolonged use (The RSVP Trial)

RSVP trialNurses currently replace AS more frequently that IVDs as they believe that this prevents infection. This is expensive and time consuming, with a poor evidence base. A meta-data analysis of almost 5,000 patients (Cochrane Collaboration, 2005) found AS replacement at any of 24. 48, 72 or 96 hours did not change infection risk (IVD-BSI RR 1.15, 95%CI 0.94, 1.42). Other data, including our pilot study (404 IVDs) found no difference in IVD colonisation or IVD-BSI between groups in 4 versus 7 days use.

The aim of the study is to compare intravascular device (IVD) administration set (AS) replacement at 4 days versus 7 days on infective and cost outcomes. The primary hypothesis is that there will be no difference in the incidence of IVD-related bloodstream infection (IVD-BSI) between patients whose AS are replaced every 4 days or 7 days. The study design will consist of a large, multi-centre, randomised controlled trial in the general hospital setting.

Consenting patients with a central venous, peripherally inserted central venous, or peripheral arterial devices to be indwelling for more than 4 days will be randomly assigned to have AS replaced every 4 or 7 days. The primary outcome measure is IVD-BSI. Secondary outcomes are: IVD colonisation, AS colonisation, all-cause BSI, phlebitis, mortality, IVD time in situ, AS use and costs. There will be a 3 year recruitment of 6,500 adult and paediatric patients, in 5 hospitals in South-East Queensland.

About 14 million IVDs are used in Australia each year. The current restriction of AS use to 3 to 4 days possibly has no benefit, yet it is costing the country approximately 1 billion dollars and 2 million nursing hours each year. Extension of AS use to 7 days would lead to significant cost, time and environmental savings.

This trial is already funded by the NHMRC.

Alliance for Vascular Access Teaching and Research Group
  • Home
  • Research
  • Connections
  • Teaching
  • About Us
  • Blog
  • Contact

Address

Griffith University
Nathan
Queensland
Australia 4111

Follow Us on

  • facebook
  • youtube
  • linkedin

Home | Contact Us | Blog | Print this page | Top of page

Phone: .
Address: Griffith University, Nathan, Queensland, Australia, 4111
Copyright © 2025 Alliance for Vascular Access Teaching and Research Group
Designed by Bloomtools